Related references
Note: Only part of the references are listed.Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab
R. A. Manneh Kopp et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma
Koos E. Hovinga et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Significance of Glioma Stem-Like Cells in the Tumor Periphery That Express High Levels of CD44 in Tumor Invasion, Early Progression, and Poor Prognosis in Glioblastoma
Masahiro Nishikawa et al.
STEM CELLS INTERNATIONAL (2018)
New Directions in Anti-Angiogenic Therapy for Glioblastoma
Nancy Wang et al.
NEUROTHERAPEUTICS (2017)
Surgical results of tumor resection using tractography-integrated navigation-guided fence-post catheter techniques and motor-evoked potentials for preservation of motor function in patients with glioblastomas near the pyramidal tracts
Shiro Ohue et al.
NEUROSURGICAL REVIEW (2015)
Differentiation, polarization, and migration of human induced pluripotent stem cell-derived neural progenitor cells co-cultured with a human glial cell line with radial glial-like characteristics
Yohei Bamba et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Glioblastoma Resistance to Anti-VEGF Therapy: Has the Challenge Been MET?
Joseph H. McCarty
CLINICAL CANCER RESEARCH (2013)
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Kan V. Lu et al.
CANCER CELL (2012)
Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
Basel Sitohy et al.
CANCER RESEARCH (2012)
Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy
Michael Delay et al.
CLINICAL CANCER RESEARCH (2012)
The Three-Layer Concentric Model of Glioblastoma: Cancer Stem Cells, Microenvironmental Regulation, and Therapeutic Implications
Luca Persano et al.
THESCIENTIFICWORLDJOURNAL (2011)
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Margot Zoeller
NATURE REVIEWS CANCER (2011)
A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis
Martina Tremmel et al.
BLOOD (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CD44: From adhesion molecules to signalling regulators
H Ponta et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity
Y Kanemura et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2002)
Effect of p53 status on tumor response to antiangiogenic therapy
JL Yu et al.
SCIENCE (2002)
Share Paper
